A retrospective study assessing efficacy and tolerability of perampanel as add-on treatment in patients (aged ≥ 12 y) with refractory focal seizures, in a real-life setting.

Trial Profile

A retrospective study assessing efficacy and tolerability of perampanel as add-on treatment in patients (aged ≥ 12 y) with refractory focal seizures, in a real-life setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2017 New trial record
    • 06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top